Is $475,000 Too High a Price for Novartis's 'Historic' Cancer Gene Therapy?
FORTUNE
A high price for a groundbreaking treatment. On Wednesday, Swiss pharmaceutical giant Novartis made history as the first company to win Food and Drug Administration (FDA) approval for a groundbreaking new type of cancer treatment known as CAR-T. This technology harnesses the power of patients' very immune cells—which are extracted from them, reengineered in a lab, and then pumped back into the body—to kill aggressive blood cancers. The treatment, named Kymriah, was hailed by doctors and the life Read the full story
Shared from Apple News
-Mark
No comments:
Post a Comment